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Abstract 11 
Several repurposed drugs are currently under investigation in the fight against coronavirus disease 12 
2019 (COVID-19). Candidates are often selected solely by their effective concentrations in vitro, an 13 
approach that has largely not lived up to expectations in COVID-19. Cell lines used in in vitro 14 
experiments are not necessarily representative of lung tissue. Yet, even if the proposed mode of 15 
action is indeed true, viral dynamics in vivo, host response, and concentration-time profiles must also 16 
be considered. Here we address the latter issue and describe a model of human SARS-CoV-2 viral 17 
kinetics with acquired immune response to investigate the dynamic impact of timing and dosing 18 
regimens of hydroxychloroquine, lopinavir/ritonavir, ivermectin, artemisinin, and nitazoxanide. 19 
We observed greatest benefits when treatments were given immediately at the time of diagnosis. 20 
Even interventions with minor antiviral effect may reduce host exposure if timed correctly. 21 
Ivermectin seems to be at least partially effective: given on positivity, peak viral load dropped by 0.3-22 
0.6 log units and exposure by 8.8-22.3%. The other drugs had little to no appreciable effect. Given 23 
how well previous clinical trial results for hydroxychloroquine and lopinavir/ritonavir are explained 24 
by the models presented here, similar strategies should be considered in future drug candidate 25 
prioritization efforts. 26 
1 Introduction 27 
Since the beginning of the ongoing global outbreak of severe acute respiratory syndrome coronavirus 28 
2 (SARS-CoV-2) a variety of drug therapies have been proposed. Some are based on expert opinion, 29 
some on promising in vitro results, some on findings in case series from compassionate or off-label 30 
treatments. Unfortunately, whenever they are put through the rigorous process of randomized clinical 31 
trials, little evidence for palpable real-world benefits remains. 32 
Novel coronavirus disease 2019 (COVID-19) spreads rapidly not only from host to host but within 33 
each host as well. The infection progresses at a staggering speed in individual patients which may 34 
become infectious after 2-3 days and reach peak viral loads only a few days after the reverse-35 
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transcriptase polymerase chain reaction (RT-PCR) test becomes positive (To et al., 2020). The need 36 
for early initiation of drug therapy has been recognized as key for successful treatment of infectious 37 
diseases, and COVID-19 is unlikely to be an exception (Gonçalves et al., 2020). 38 
The repurposing of drugs with established supply chains and low manufacturing costs seems the 39 
straightest path towards a timely pharmacological intervention. Because our understanding of the 40 
pathophysiology of COVID-19 is still evolving, the selection of viable candidates is mostly dictated 41 
by extrapolations from in vitro and in silico evidence. Identified drug targets include the viral 42 
structural spike (S) protein; the host type 2 transmembrane serine protease (TMPRSS2); 3-43 
chymotrypsin-like (3CL) protease mediating proteolysis; RNA-dependent RNA polymerase; and 44 
interleukin-6 receptors (Arshad et al.;Sanders et al., 2020). 45 
A basic tenant of clinical pharmacology states that unbound drug must reach its target at sufficient 46 
concentrations (e.g. half-maximal effective target concentrations (EC50)) and maintain them to exert 47 
effects. This is a common criterion for drug candidate selection and has been applied to COVID-19 48 
early on in well-conducted comprehensive surveys (Arshad et al.). Unfortunately, the candidates with 49 
highest probability of success have largely failed in practice, and it appears the EC50 approach might 50 
be too simplistic for this disease, as it is not only important whether EC50 is reached, but also for how 51 
long concentrations (above EC50) can be maintained, especially at the target site. 52 
One reason may be failure to account for host factors. For instance, a crucial element of treatment 53 
response is host immunity. There are in vivo studies on the temporal dynamics of immune response 54 
and seroconversion (Long et al., 2020;To et al., 2020;Young et al., 2020). Early suppression of viral 55 
load even for brief periods may be beneficial by providing more time for the host to mount a defense 56 
and assist in clearing an otherwise overwhelming infection. 57 
The viral kinetics of several diseases have been successfully described mathematically in the past, 58 
e.g. influenza, hepatitis C, or Ebola (Beauchemin and Handel, 2011;Canini and Perelson, 2014;Oakes 59 
et al., 2018). For COVID-19, Kim et al. used a target cell limited model to show the importance of 60 
early initiation of treatment and drug mode of action (Kim et al., 2020b). Other authors arrive at 61 
similar results with eclipse models (Czuppon et al., 2020;Gonçalves et al., 2020;Hernandez-Vargas 62 
and Velasco-Hernandez, 2020). None of these studies however directly used pharmacokinetic 63 
profiles in their models. 64 
With this modeling and simulation study we aimed to understand the influence of different modes of 65 
action, concentration profiles, dosing schedules, and timing of interventions on key parameters of 66 
viral load (peak load, duration of positivity, and total exposure as measured by area under the curve 67 
(AUC)) in acute COVID-19. We developed a model of the within-host viral kinetics of SARS-CoV-2 68 
from published patient data and drove antiviral effect with simulated pharmacokinetic (PK) profiles 69 
of selected drugs with different dose regimens. These drugs include hydroxychloroquine (HCQ, 70 
considered a blocker of viral entry), ritonavir-boosted lopinavir (LPV/r, a 3CL inhibitor), ivermectin 71 
(IVM, a broad spectrum anthelminthic with antiviral activity), nitazoxanide (NZT, an antiparasitic 72 
agent with antiviral activity), and artemisinin (ART, the primary component of sweet wormwood, 73 
believed to inhibit viral entry and intracellular reproduction of SARS-CoV-2) (Li et al., 2005;Caly et 74 
al., 2020;Choy et al., 2020;Gordon et al., 2020;Liu et al., 2020;Wang et al., 2020a;Wu et al., 2020). 75 
Our selection was influenced by perceived research interest (HCQ, LPV/r, NZT) and lay use of drugs 76 
in the general public as self-medication (HCQ, IVM, ART) (Martins-Filho et al., 2020;Molento, 77 
2020;Nordling, 2020;Owens, 2020;WHO, 2020). Although remdesivir has so far shown the greatest 78 
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promise, there is currently not enough published data to allow for pharmacometric simulation in the 79 
model proposed here, and hence the drug was not included (Beigel et al., 2020). 80 
2 Methods 81 
2.1 Data sources 82 
Viral kinetic profiles of COVID-19 patients were taken from Young et al. (Young et al., 2020), a 83 
study that followed the first patients (n=18) in four hospitals in Singapore (Chinese nationals: n=16, 84 
Singapore residents: n=2). We read out values using a digitizing software. Most (n=13) were not on 85 
specific therapy and were included in the analysis. Viral load was measured from nasopharyngeal 86 
swabs with RT-PCR and presented in cycle threshold (Ct) values (Young et al., 2020). As the 87 
correlation between Ct values and viral load varies by laboratory and analytical conditions, we chose 88 
to relate model output with observed Ct values with a published regression fit (Chu et al., 2020). 89 
Since the time of infection was not recorded, this value had to be estimated. Although the incubation 90 
period varies between patients, an average incubation period of 5 days fitted well for all patients 91 
(Lauer et al., 2020). We fixed the positivity threshold at 35 cycles, corresponding to 101.58 copies/mL 92 
(Wang et al., 2020b). 93 
2.2 Viral kinetics models 94 
In the standard target cell limited model, virus particles V infect a pool of susceptible (target) cells T 95 
with the cellular infection rate β. Infected cells I begin shedding virions at a production rate p (Canini 96 
and Perelson, 2014). The parameters c and δ determine the rate of clearance of virus and cell death of 97 
infected cells, respectively. The time-dependent number of susceptible cells (Eq. 1), infected cells 98 
(Eq. 2) and viral load (Eq. 3) are described by a system of ordinary differential equations as follows: 99 
=  −(1 − 𝜂)𝛽𝑇𝑉    (1) 100 
= (1 − 𝜂)𝛽𝑇𝑉 −  𝛿𝐼   (2)  101 
= (1 − 𝜀)𝑝𝐼 − 𝑐𝑉   (3) 102 
The effects of pharmacological treatments by different modes of action are described by the 103 
following variables: inhibition of viral entry into susceptible cells, by decreasing the cellular 104 
infection rate with effectiveness η, and/or by blocking viral production rate within infected cells with 105 
effectiveness ε. We modeled treatment effect based on the IC50 or EC50 values of the drugs on their 106 
respective targets using a sigmoidal Emax model (Eq. 4), with C(t) being the concentration of the drug 107 
at a given time: 108 
𝜀 𝑜𝑟 𝜂 =  
 × ( )
( )
  (4) 109 
We also considered an eclipse model, an extension in which infected cells enter an eclipse phase (E) 110 
for an average duration 𝑘  until they begin shedding virions. Initial conditions were set as  111 
𝑇(0) = 𝑇 , 112 
𝑉(0) = 𝑉 , 113 
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𝐼(0) = 0, 114 
and additionally, for the eclipse model, 115 
𝐸(0) = 0 116 
where T0 is the number of susceptible cells fixed to 1 × 10  (based on prior modeling efforts and 117 
accounting for ~1% of alveolar cells expressing ACE2, the main point of entry for SARS-CoV-2) 118 
(Baccam et al., 2006;Li et al., 2020b), V0 the initial viral load on inoculation (fixed at 1 × 10  119 
copies/mL), and E0 the number of cells in eclipse state. The within-host reproduction number R0 was 120 
set to 3.79 (Li et al., 2020a). This value is also approximately in the same range as other within-host 121 
virus kinetic models (Hernandez-Vargas and Velasco-Hernandez, 2020;Kim et al., 2020b). Other 122 
parameters need to be estimated by numerical optimization, i.e. viral clearance c, the production rate 123 
p, and the death rate of infected cells δ. The cellular infection rate β of the virus is dynamically 124 
calculated (Eq. 5). 125 
𝛽 =
( )
   (5) 126 
Supplementary Table S2 shows all model parameters and sources. 127 
2.3 Immune response 128 
Our understanding of SARS-CoV-2 immunity is still evolving. Immunity could involve cells entering 129 
into a refractory state or an antibody mediated increase in viral clearance. Adding an additional state 130 
would increase model complexity beyond what seems supported by the source data. We therefore 131 
chose to enter acquired immune response as a time-dependent covariate effect on viral clearance c. 132 
Temporal dynamics are based on Long et al. (Long et al., 2020) who evaluated seroconversion for 133 
IgM and IgG in 285 patients from three hospitals in Chongqing (neighboring Hubei Province). Data 134 
were extracted with a digitizing software and fitted to a sigmoidal Emax model. As effect size of the 135 
immune response in SARS-CoV-2 infection (Emax, immunity) is unknown, we estimated this value 136 
together with the models of viral kinetics.  137 
2.4 Pharmacokinetic models 138 
We simulated pharmacokinetics (PK) of HCQ, IVM, LPV/r and ART from published population 139 
pharmacokinetics models. Profiles for HCQ were simulated from healthy volunteers reported by Lim 140 
et al. (Lim et al., 2009) The IVM model was taken from Duthaler et al. and simulated using fed state 141 
dosing (Duthaler et al., 2019). The LPV/r model by Dickinson et al. (Dickinson et al., 2011) was 142 
built from data of healthy volunteers receiving 400/100mg, the dose that was under investigation in 143 
WHO Solidarity. For ART we directly implemented the model developed by Birgersson et al. in 144 
healthy male volunteers with a dosing regimen of 500 mg daily for 5 days (similar to historical 145 
dosing recommendations in malaria) (Birgersson et al., 2016). No published pharmacometric model 146 
is available for NTZ. The drug is rapidly and completely hydrolysed to an active metabolite, 147 
tizoxanide (TZ). We therefore extracted the mean TZ pharmacokinetic profile from a study in healthy 148 
Mexican volunteers with a digitizing software, fitted a one-compartment oral absorption model with 149 
lag time, and used this for simulation (Balderas-Acata et al., 2011). 150 
As the protein-bound fraction of a drug is considered not to interact with its target, we considered 151 
only the unbound fraction of the drugs where available (Supplementary Table S2). i.e. 50% for 152 
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HCQ (Furst, 1996), 7% for IVM (Klotz et al., 1990), 1% for NTZ (FDA, 2005), and 1% for LPV 153 
(Boffito et al., 2004). No human in vivo data exist for lung concentrations in any of the drugs in this 154 
study. We used literature-based approximations to adjust for differences between plasma and lung 155 
concentration profiles. The issue of lung tissue concentrations is particularly contentious for HCQ, 156 
with some reports of lung:plasma ratio ranging from 27 to 177 in macaques (Maisonnasse et al., 157 
2020). Recent evidence suggests that in COVID-19 HCQ plasma concentrations are more 158 
representative (Fan et al., 2020). For IVM lung accumulation, we used cattle data published by 159 
Lifschitz et al., an approach also used in another publication discussing the potential role of IVM in 160 
COVID-19 (Lifschitz et al., 2000;Schmith et al., 2020). LPV concentrations in lung tissue were 161 
assumed to be 1.78 times higher than in plasma, and protein binding was set to 99% (Atzori et al., 162 
2003;FDA, 2013). For NTZ we used estimates from a recently pre-published physiology-based 163 
pharmacokinetic (PBPK) model for lung partitioning (Rajoli et al., 2020). 164 
2.5 Pharmacodynamic effects 165 
The effectiveness of HCQ was shown in vitro in Vero E6 cells by Liu et al. (Liu et al., 2020). The 166 
EC50 values at 48h ranged between 4.06 and 12.96 µM, depending on the amount inoculated. We 167 
enter the mean of these values (8.51 µM) as an effect on the reduction of the cellular infection rate β. 168 
We simulated dosages of 200 mg q8h for 10 days as proposed by Gautret et al. and the scheme 169 
previously employed in the WHO Solidarity trial, 800 mg q12h on the first day (loading dose) and 170 
400 mg q12h on day 2-10 (Gautret et al., 2020;WHO, 2020). 171 
For IVM, we assumed two pharmacodynamic effects: the inhibition of RNA helicase and inhibition 172 
of nicotinic acetylcholine receptors (nAChR). The inhibitory effect of IVM on helicase has been 173 
previously reported for flaviviridae, i.e. yellow fever virus (YFV, IC50 0.12 µM), Dengue virus 174 
(DENV, IC50 0.5 µM), and West Nile Virus (WNV, IC50 0.35 µM) (Mastrangelo et al., 2012). There 175 
are no in vitro data for SARS-CoV-2 yet, although Caly et al. (Caly et al., 2020) have reported a 176 
strong maximal inhibition of virus replication in the Vero E6 cell line with an IC50 of about 2 µM. 177 
Higher concentrations (10-25 µM) need to be achieved for similar inhibition of DENV replication 178 
(Wagstaff et al., 2012). The difficulties in achieving micromolar concentrations have led some 179 
authors to speculate IVM is not druggable in the context of COVID-19 (Bray et al., 2020). Strikingly, 180 
despite the higher IC50 in DENV infected Vero E6 cells, a small trial of IVM 3x400 µg/kg in DENV 181 
patients demonstrated antiviral effects in vivo (Yamasmith et al., 2018). Due to the higher 182 
susceptibility of SARS-CoV-2 to IVM than DENV in Vero E6 cells, we used a conservatively 183 
reduced IC50 of 0.1 µM in the simulations as an inhibitory influence on viral production p. 184 
In addition, IVM interacts with nAChR (IC50 156 nM) (Degani-Katzav et al., 2017). It has been 185 
hypothesized that inhibition of nAChR downregulates angiotensin-converting enzyme 2 (ACE2) 186 
expression and thus reduces the points of entry for SARS-CoV-2 (Oakes et al., 2018). We enter this 187 
as a net inhibitory effect on the cellular infection rate β. In contrast to direct inhibition of viral entry, 188 
this is an antiviral activity mediated by the host and therefore not easily captured in in vitro assays. 189 
For IVM, we evaluated 300 µg/kg and 600 µg/kg q24h for three days. These dosages are not 190 
approved, but safety and tolerability of single fixed doses of 120 mg were shown previously in 191 
healthy volunteers (Guzzo et al., 2002). 192 
LPV and RTV are both protease inhibitors. Their use in COVID-19 was investigated as a now 193 
discontinued arm of the WHO solidarity trial (LPV 400 mg and RTV 100 mg q12h for 14 d) (WHO, 194 
2020). LPV reduced the viral RNA copies of SARS-CoV-2 in vitro with an EC50 of 26.1 µM, 195 
whereas RTV has an EC50>100 µM (Choy et al., 2020). As RTV in this co-formulation (LPV/r) is 196 
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only intended to boost the bioavailability of LPV, we only consider the antiviral effect of LPV on the 197 
viral production rate p (Chandwani and Shuter, 2008). 198 
ART as the main component of A. annua (sweet wormwood) extract has not been studied in SARS-199 
CoV-2. Nair et al. reported an antiviral effect in Vero E6 cells of artesiminin on SARS-CoV-2 with 200 
an EC50 of 19.8 µg/ml (=70 µM) (Nair et al., 2021). Studies suggest that artemisinin interferes with 201 
viral entry by interaction with the spike protein (Sehailia and Chemat, 2020), but also effects post-202 
entry steps of infection (Cao et al., 2020b;Nair et al., 2021) We entered this as an effect on viral 203 
production rate p and the cellular infection rate β. 204 
NTZ has shown in vitro activity against SARS-CoV-2 in Vero E6 cells at an EC50 of 2.12 µM (Wang 205 
et al., 2020a). The mechanism of action is unclear but it has been hypothesized that NTZ inhibits 206 
viral entry as well as replication. We used both effects in the simulations (Arshad et al.). 207 
2.6 Software 208 
We modelled and simulated pharmacokinetic profiles with Pkanalix and mlxR (version 4.1.3), an R 209 
package for interfacing with Monolix (version 2019R2, http://www.lixoft.com, Antony, France). 210 
Data for viral loads and NTZ were read out with WebPlotDigitizer (version 4.2, 211 
https://automeris.io/WebPlotDigitizer). Immunity Emax and EC50 were estimated using the R package 212 
rstanemax (version 0.1.2). Data checkout, analysis and visualization were performed in GNU R 213 
(version 3.6.3, R Foundation for Statistical Computing, http://www.R-project.org, Vienna, Austria). 214 
Ordinary differential equation (ODE) systems and parameter estimations were implemented with the 215 
R packages deSolve (version 1.28) and dfoptim (version 2018.2-1).  216 
3 Results 217 
3.1 Viral kinetics models 218 
We used the viral load profiles of untreated patients published by Young et al. (n=13, supplemental 219 
material) (Young et al., 2020). We evaluated target cell limited and eclipse models, both with a time-220 
varying effect on viral clearance c following a sigmoidal Emax model fitted to reported seroconversion 221 
data (Long et al., 2020). The averaged parameters estimates from individual profiles with the Nelder-222 
Mead method were (see also Supplementary Table S1 and Supplementary Figure S1):  223 
- viral clearance c: 5.07, 224 
- production rate p: 10.2,  225 
- death rate of infected cells δ: 0.54, and  226 
- maximal immune effect on clearance Emax,immunity: 57.0 227 
Non-linear mixed effects implementations of these models proved less robust to changes in initial 228 
estimates and suffered from numerical identifiability problems.  229 
Profiles were best described by a standard target cell limited model. The addition of an eclipse phase 230 
did not improve fits and also introduced identifiability issues, as was already noted in another study 231 
(Hernandez-Vargas and Velasco-Hernandez, 2020). Left untreated, viral load exceeds the RT-PCR 232 
positivity threshold of 35 cycles at 5.4 dpi, peaks at 10.4 dpi with a Ct value of 28.4 cycles, and drops 233 
below the positivity limit at 18.9 dpi, similar to reports from clinical studies (Kim et al., 2020a;Lauer 234 
et al., 2020;To et al., 2020). Total viral exposure (measured as AUC) was 235 
12’003 days*log(copies/mL).  236 
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3.2 Dosage and effectiveness of treatment 237 
Temporal impact of treatment is shown as individual curves in Figure 1. Effect on viral exposure as 238 
difference in area under the curve (AUC), relative change in duration, and change in peak cycle (Ct) 239 
are presented in Figure 2. Full results including changes in peak viral load and duration of disease 240 
are available in Supplementary Table S3 and Supplementary Figure S2. The PK curves of the 241 
treatments and the corresponding effect on SARS-CoV-2 viral kinetics are shown in Supplementary 242 
Figure S2 – S5. 243 
HCQ reduced peak viral load by 0.2-0.3 log units and exposure by 4.6-8.2% when given on 244 
positivity. Treatment started around peak viral load (10.2 dpi) had no appreciable effect on total viral 245 
load or duration of disease. Between both dose regimens, the WHO Solidarity trial arm resulted in 246 
the more pronounced reduction in total viral load. Effects of IVM were more pronounced: given on 247 
positivity, peak viral load dropped by 0.3-0.6 log units and exposure by 8.8-22.3 %. Exposure 248 
reductions are associated with slightly prolonged durations of shedding from 13.5 days (untreated) to 249 
14.2-15.6 days for IVM and 14.1-14.5 days for HCQ, and a shift of Tmax from day 10.2 (untreated) to 250 
day 10.9-12.3 and day 10.5-10.9, respectively. Interestingly – and in contrast to HCQ – some effects 251 
remain when treatment is initiated around peak viral load (3.4-13.2 % difference in exposure). LPV/r, 252 
ART and NTZ had no influence on viral dynamics, independent of time of initiation. 253 
4 Discussion 254 
Our modeling and simulation study described patient viral load well and captured the essential 255 
milestones of SARS-CoV-2 viral kinetics, e.g. duration of viral shedding, and peak viral loads. It also 256 
shows that the window of opportunity to treat COVID-19 is narrow. As the infection spreads rapidly 257 
throughout the host, the pool of susceptible cells is quickly depleted. Drugs inhibiting viral entry 258 
(like HCQ) therefore only appear to have a role, if any, in the first days after inoculation (post-259 
exposure prophylaxis) or as primary prophylactic agents handed out to at-risk individuals.  260 
These findings may help to explain the disappointing results of clinical trials with HCQ: by the time 261 
patients are hospitalized or even transferred to critical care, few susceptible cells are left, so little 262 
impact can be made at this point (Annie et al., 2020;Cavalcanti et al., 2020 ;Molina et al., 2020;Tang 263 
et al., 2020a). The WHO Solidarity trial’s dosing scheme was clearly more effective than the one 264 
proposed by Gautret et al. (Gautret et al., 2020). However, even with the higher dosing scheme used 265 
in the WHO Solidarity trial, no appreciable effect of HCQ was observed and the treatment arm was 266 
prematurely terminated on June 18, 2020 (Pan et al., 2020). Of note, recent trials have also failed to 267 
find benefits for HCQ in pre- and post-exposure prophylactic indications (Boulware et al., 268 
2020;Rajasingham et al., 2020). Since viral load is not the only determinant of disease state, one 269 
cannot directly deduce clinical effect of any of the regimens from these simulations. Given the 270 
negative results of previous trials with HCQ, we suggest that HCQ results should be used as a lower 271 
threshold to rank other drugs against. 272 
We found greatest effects for IVM. Again, the earlier and longer the exposure, the better, but 273 
compounds like IVM still convey some benefit if initiated at a later stage. When held to the HCQ 274 
benchmark, IVM 600 µg/kg daily for 3 days, particularly when given around time of positivity, may 275 
have meaningful impact whereas IVM 300 µg/kg daily for 3 days had efficacy comparable to HCQ 276 
regimens. This finding is in contrast to other analyses suggesting IVM is poorly druggable in 277 
COVID-19, e.g. (Schmith et al., 2020). It is important to stress that these IVM doses, while 278 
apparently safe in healthy volunteers, are far higher than any dose approved for other indications 279 
(1x200 µg/kg to 1x400 µg/kg). At 3x600 µg/kg in a 70 kg patient, doses are similar to the maximum 280 
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doses (120 mg single administration) described by Guzzo et al. (Guzzo et al., 2002). Boosting 281 
exposure to IVM by co-administering inhibitors of its metabolism or elimination (such as the 282 
CYP3A4 and P-glycoprotein (P-gp) inhibitor ritonavir) is a theoretical option (Chaccour et al., 2017). 283 
However, there are concerns that inhibition of P-gp as an integral part of the functional blood brain 284 
barrier could lead to more central nervous adverse events (Chandler, 2018). Until this interaction has 285 
been studied systematically, it seems unwise to explore this strategy. For IVM, no results of clinical 286 
trials regarding its effectiveness in Covid-19 have been published yet. 287 
ART, NTZ and LPV/r had no noteworthy effect and do not appear suitable candidates for follow-up 288 
at this point. We attribute this in part to their strong protein binding (88-99%), leaving little free drug 289 
to engage with targets. Additionally, the EC50 for ART is rather high at 70 µM and not likely to be 290 
even partially achieved. For LPV/r our findings are confirmed by clinical trial results (Cao et al., 291 
2020a, 24), notably the RECOVERY trial (University of Oxford, 2020) and the WHO Solidarity trial, 292 
who discontinued the LPV/r treatment arm on July 4, 2020 (Pan et al., 2020). As of now, no trials on 293 
NTZ and ART have reported results.  294 
Our study has several limitations. Our model parameter estimates are based on assumptions of 295 
incubation time and number of target cells in the lungs, both of which introduce bias. Covid-19 was 296 
initially described from a cluster of pneumonia cases, and while symptoms of the upper and lower 297 
airways are most recognizable, vascular, thromboembolic, gastrointestinal, and neurological 298 
symptoms have been widely described (Klok et al., 2020;Mao et al., 2020;Struyf et al., 2020;Zhang 299 
et al., 2020). Expression levels of ACE2 are also much higher in other tissues, e.g. the small intestine, 300 
the kidneys, and the heart (Li et al., 2020b). Hence it seems unlikely that systemic viral loads are 301 
solely a product of alveolar epithelial cells. Extent of viral burden is dependent on disease severity 302 
and also site of sampling (e.g. oropharyngeal, nasopharyngeal, plasma (Fajnzylber et al., 2020)). 303 
Ethnicity is thought to affect clinical outcomes (Sze et al., 2020), yet there is inconclusive evidence 304 
as to the impact of ethnicity on viral load (Magleby et al., 2020). In conclusion, we suggest that the 305 
size of the pool of target cells be re-estimated in different populations. 306 
Point estimates of viral kinetics parameters yielded realistic estimates of viral load profiles with 307 
reasonable uncertainty around point estimates (%CV: 30-43). We did not normalize the 308 
asynchronous dynamics of the source data (e.g. viral peak at different dpi), which might have 309 
improved fits. However, currently no accepted procedure exists (Hernandez-Vargas, 2019). Other 310 
authors have used more sophisticated methods such as non-linear mixed effects (nlme) modeling on 311 
the same source data, implementing other structural models such as eclipse models (Czuppon et al., 312 
2020;Gonçalves et al., 2020). Our nlme implementations of the models suffered from the same 313 
numerical identifiability issues seen by other authors (Hernandez-Vargas and Velasco-Hernandez, 314 
2020). Given that the model presented here is structurally different from other target cell limited or 315 
eclipse models, some point estimates can differ from other implementations (such as the reproduction 316 
number R0, or number of susceptible cells T0, eg. (Gonçalves et al., 2020)). 317 
Virus extinction is not captured by any models like the one proposed here. We therefore decided not 318 
to model prophylactic dosing (prior to or on exposure), and resorted to return to negativity on RT-319 
PCR as a surrogate measure for disease duration. This is supported by data suggesting that late stage 320 
shedding is of non-infectious virus particles only (Walsh et al., 2020). 321 
We made several assumptions on modes of drug action and their efficacy. We used the published 322 
mode of action of HCQ on SARS-CoV-2, which were performed in the African green monkey 323 
kidney-derived cell line Vero (Wang et al., 2020a), even though there is evidence that this cell line 324 
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might not be suitable to represent lung tissue (Hoffmann et al., 2020). The model places HCQ effects 325 
only on viral entry, although it might also have other modes of actions which might affect the 326 
production of virions within infected cells (Quiros Roldan et al., 2020;Tripathy et al., 2020). 327 
Additionally, HCQ has immunomodulatory effects and might hinder the activation of B and T cells 328 
and thus inhibit the host-innate immune response (Goldman et al., 2000;Quiros Roldan et al., 2020). 329 
No data for SARS-CoV-2 were available for modeling. If relevant at all, our model would be 330 
overestimating the effectiveness of HCQ.  331 
The in vitro evidence of efficacy of IVM against SARS-CoV-2 is not detailed enough to model 332 
effects with greater precision. Based on data from other flaviviridae, particularly Dengue virus, the 333 
proposed inhibition of replication seems reasonable (Mastrangelo et al., 2012). Inclusion of effects on 334 
viral entry follows pathophysiological reasoning and has yet to be confirmed in studies. IVM engages 335 
with nAChR, which leads to a reduction of ACE2 and in turn decreases the points of entry for SARS-336 
CoV-2, influencing the cellular infection rate. Even though the IC50 for IVM on nAChR has been 337 
experimentally determined, we do not know how exactly this relates to the reduction of ACE2 338 
expression. Therefore, we decided to model it solely based on plasma levels and the available IC50. 339 
In HCQ and IVM, even though total viral load is reduced, the duration of virus shedding might be 340 
increased, a consequence of a ‘flattening of the curve’ similar to what is observed on a population 341 
scale. However, this gives the immune response more time to develop an immune response. For this 342 
reason, overall total viral load decreases in the simulated models. Changes in peak viral load were 343 
moderate at best (< 1 log unit). While convenient endpoints to measure in a clinical setting, AUCs of 344 
viral load appear more appropriate for drug discovery.  345 
ART and NZT have only recently received attention in COVID-19 treatment. Despite having little 346 
effect in our study they would make excellent candidates from economic and logistic points of view. 347 
We selected ART as it is the primary active ingredient in sweet wormwood. Herbal concoctions of 348 
wormwood are being promoted as a cheap, easily accessible form of self-medication in COVID-19 349 
(Deutsche Welle, 2020). A. annua and derivatives (artesunate, dihydroartesunate) are widely used as 350 
antimalarials. Effective concentrations have yet to be determined for ART and its derivatives, 351 
although the large degrees of protein binding imply that effective target concentrations need to be in 352 
the low micromolar range. Studies suggest that artemisinin has also anti-inflammatory and 353 
immunomodulatory effects, which might be beneficial when treating COVID-19 (Tang et al., 2020b). 354 
However, as these effects are not related to the viral kinetic, we were not able to include these in our 355 
simulations. Even then its use would have one crucial limitation: the WHO is discouraging use of 356 
oral artemisinin monotherapy (AMT) in malaria as it is considered to be a major factor for the 357 
development of parasite resistance (WHO, 2014). A renaissance of oral AMT in malaria endemic 358 
regions during the ongoing COVID-19 pandemic could cause more harm than good. 359 
For NTZ, pharmacokinetic simulations were based on a mean curve of a single dose of NTZ 500 mg. 360 
The EC50 value was determined for NTZ, not the immediately formed active metabolite tiaxozanide, 361 
which would be the active compound expected to reach tissue (Wang et al., 2020a). When more 362 
detailed results for tiaxozanide are available, simulated efficacy could change.  363 
In conclusion, while in vitro studies are very well suited to identify possible modes of actions of 364 
potential treatments for COVID-19, they are unable to predict the clinical efficacy of a drug. Our 365 
simulation of treatments fitted well with available results from clinical trials, even though several 366 
estimations had to be made and limitations accepted. Although early initiation was a strong 367 
determinant for treatment effect, none of the interventions studied showed major impact on viral 368 
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dynamics. Efforts should focus on identification of more efficacious drug candidates and vaccine 369 
development. Until then, general social and hygiene measures remain the best interventions to 370 
combat COVID-19.  371 
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 713 
Figure captions 714 
Figure 1 - Viral load profiles of SARS-CoV-2 following different treatment regimens and initiation 715 
of treatment (green: untreated, blue: on positivity (5.4 days post infection), red: on peak (10.2 days 716 
post infection)). Lines may overlap so that only one color is visible; simulations were always run for 717 
all time points. Ct: serial cycle threshold values; ART: artemisinin; HCQ: hydroxychloroquine IVM: 718 
ivermectin; LPV/r: lopinavir/ritonavir; NTZ: nitazoxanide. Dosing of different modeled treatment 719 
regimens: HCQ 200: 200 mg every 8h for 10 days; HCQ 800: 800 mg every 12h for 1 day, then 400 720 
mg every 12h for 9 days; IVM 300: 300 μg/kg every 24h for 3 days; IVM 600: IVM 600 μg/kg every 721 
day for 3 days; NTZ 1200: NTZ 1200 mg every 6h for 5 days; NTZ 2900: NTZ 2900 mg every 12h 722 
for 5 days; ART 500: ART 500 mg once a day for 5 days; LPV/r 400/100: LPV/r 400/100 mg every 723 
12h for 14 days. 724 
Figure 2 – Treatment effects on viral exposure as difference in area under the curve (AUC), relative 725 
change in duration, and change in peak cycles (Ct) following different initiation time of treatment (on 726 
positivity: 5.4 days post infection, on peak: 10.2 days post infection). HCQ: hydroxychloroquine; 727 
IVM: ivermectin; NTZ: nitazoxanide; ART: artemisinin; LPV/r: lopinavir/ritonavir. Dosing of 728 
different modeled treatment regimens: HCQ 200: 200 mg every 8h for 10 days; HCQ 800: 800 mg 729 
every 12h for 1 day, then 400 mg every 12h for 9 days; IVM 300: 300 μg/kg every 24h for 3 days; 730 
IVM 600: IVM 600 μg/kg every day for 3 days; NTZ 1200: NTZ 1200 mg every 6h for 5 days; NTZ 731 
2900: NTZ 2900 mg every 12h for 5 days; ART 500: ART 500 mg once a day for 5 days; LPV/r 732 
400/100: LPV/r 400/100 mg every 12h for 14 days. 733 
 734 
